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The underpinnings of STAT3 hyperphosphorylation resulting in
enhanced signaling and cancer progression are incompletely un-
derstood. Loss-of-function mutations of enzymes that dephos-
phorylate STAT3, such as receptor protein tyrosine phosphatases,
which are encoded by the PTPR gene family, represent a plausible
mechanism of STAT3 hyperactivation. We analyzed whole exome
sequencing (n = 374) and reverse-phase protein array data (n =
212) from head and neck squamous cell carcinomas (HNSCCs). PTPR
mutations are most common and are associated with significantly
increased phospho-STAT3 expression in HNSCC tumors. Expression
of receptor-like protein tyrosine phosphatase T (PTPRT) mutant
proteins induces STAT3 phosphorylation and cell survival, consis-
tent with a “driver” phenotype. Computational modeling reveals
functional consequences of PTPRT mutations on phospho-tyrosine–
substrate interactions. A high mutation rate (30%) of PTPRs was
found in HNSCC and 14 other solid tumors, suggesting that PTPR
alterations, in particular PTPRT mutations, may define a subset of
patients where STAT3 pathway inhibitors hold particular promise
as effective therapeutic agents.
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Tyrosine phosphorylation regulates a multitude of cellularprocesses by coordinately activating and inactivating signal-
ing proteins. Aberrations of protein tyrosine phosphorylation
and signaling are a hallmark for oncogenic events found in most
human cancers. The phosphorylation/dephosphorylation of ty-
rosine residues on signaling proteins is directly mediated by
protein tyrosine kinases and phosphatases. Although many cel-
lular factors are known to dynamically control the activity of
these enzymes, genetic alterations of kinases and phosphatases in
human cancers lead to perturbations in the levels of tyrosine
phosphorylated proteins, uncontrolled cell growth, and tumor
formation. Although activating mutations of tyrosine kinases
have been extensively studied (1, 2), cancer-associated mutations
of tyrosine phosphatases remain incompletely understood, partly
due to the lack of comprehensive genomic analysis of these large
arrays of phosphatases, as well as their largely unknown and often
ambiguous actions in normal physiology and cancer biology.
Among the 107 known protein tyrosine phosphatases, the re-
ceptor protein tyrosine phosphatases (RPTPs) represent the
largest family of the human tyrosine phosphatome, comprising
21 family members (3). These RPTPs are believed to be crucial
for the regulation of inter- as well as intracellular signaling due
to the cell-surface localization of RPTPs. Selected members
of the RPTP family have been reported to function as tumor
suppressors, where gene mutation, deletion, or methylation
may contribute to the cancer phenotype (3).
STAT3 is an oncogene, and constitutive STAT3 activation is
a hallmark of human cancers. Activating STAT3 mutations are
rare in all cancers studied to date, including head and neck
squamous cell carcinoma (HNSCC) (4). Although activating
mutations of upstream receptor tyrosine kinases leading to in-
creased STAT3 phosphorylation characterize some malignancies
[e.g., EGFR mutations in non-small cell lung cancer (5)], most
cancers lack these alterations yet harbor elevated phospho-
STAT3 (p-STAT3) levels. We (Z.W.) previously reported that
STAT3 serves as a substrate for wild-type PTPRT enzyme (also
known as RPTP-T, RPTPρ, or RPTPrho) in colorectal cancer
cells (SW480 and HT29) and HEK293T cells (6). STAT3 has
additionally been reported to be a substrate of PTPRD (also
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known as PTPδ) in glioblastoma models, suggesting that several
RPTP family members may exhibit tumor-suppressive function
by dephosphorylating STAT3 (7). In the present study, we hy-
pothesized that mutation of RPTP family members, including
PTPRT, results in elevated expression levels of tyrosine phosphor-
ylated STAT3 in humanHNSCC.Analysis of reverse-phase protein
array and sequencing data demonstrated significant association
between PTPR mutation and increased p-STAT3 expression levels
in HNSCC, establishing the de novo signaling consequence of
PTPR mutations on a major oncogenic pathway that drives human
carcinogenesis. Studies in HNSCC models demonstrate that
PTPRT mutations induce p-STAT3 and HNSCC survival, consis-
tent with a “driver” phenotype whereas computational modeling
revealed functional implications of PTPR mutations on phospho-
tyrosine (p-Tyr)–substrate interactions. Analysis of whole-exome
sequencing results of 374 primary head and neck squamous cell
carcinomas (HNSCCs) revealed that PTPR genes are mutated in
nearly one-third (30.7%) of HNSCC tumors, compared with a
15.2% mutation rate in the cytoplasmic protein tyrosine phospha-
tase (PTP) family. This pattern is strikingly consistent across an
additional 14 types of solid tumors sequenced to date, implicating
a potentially important pathologic contribution of PTPRmutations
to human carcinogenesis. These cumulative findings suggest that
genetic alterations of selected PTPRs, including PTPRT, may in-
duce STAT3 activation and serve as predictive biomarkers for
treatment with emerging STAT3 pathway inhibitors.
Results
PTPR Mutations Significantly Correlate with in Situ p-STAT3(Y705) Up-
Regulation in HNSCC Patient Tumors. To date, associations between
PTPR alterations and human cancers have relied on cell-line
models. It remains undetermined whether tumor-specific mutations
of these key tyrosine phosphatases mediate STAT3 hyperactivation
in human tumors, including HNSCC. Using reverse phase pro-
tein array (RPPA), we conducted an integrative proteomic-
genomic analysis on HNSCC patient tumors. We sought to de-
termine whether PTPR mutation is correlated with altered
STAT3(Y705) phosphorylation in primary HNSCC tumor speci-
mens. Strikingly, examination of 212 HNSCC primary tumors
showed that tumors harboring mutations in PTPR tumor sup-
pressor genes (including PTPRD/J/K/M/O/S/T) (3) expressed sig-
nificantly higher levels of p-STAT3(Y705) compared with tumors
with wild-type PTPR family members (P = 0.02) (Fig. 1A). These
results provide evidence of a direct association between PTPR
mutation and elevated STAT3 phosphorylation/activation in
human tumors in situ and establish a plausible mechanism for
STAT3 hyperactivation in human cancers. In contrast, we ob-
served no correlation between p-STAT3(Y705) expression and
epidermal growth factor receptor (EGFR), p-EGFR(Y1068), p-
EGFR(Y1173), suppressor of cytokine signaling (SOCS), Src, or
interleukin 6 (IL6) expression. Additionally, HNSCC tumors
harboring multiple PTPR mutations exhibited an even greater
increase in p-STAT3(Y705) expression although the number of
tumors in these groups is insufficient for statistical analysis (n =
14, 2, 1, or 1, for tumors with 2, 3, 4, or 5 PTPR mutations per
tumor, respectively). Upregulation of p-STAT3(Y705) was
further confirmed by immunohistochemistry in HNSCC tumors
harboring PTPR mutations (Fig. S1) and in HNSCC cell lines
harboring endogenous PTPR mutations (Fig. S2).
PTPRT Mutations “Drive” HNSCC Cell Survival and STAT3 Activation.
The biologic/functional consequences of tumor-derived PTPR
mutations in HNSCC are unknown. To determine whether
HNSCC PTPRT mutations act as “drivers,” we developed a se-
rum-dependent HNSCC cell line (PCI-52-SD1) that undergoes
rapid cell death in the absence of serum. Using this model, stable
expression of two representative mutants (calculated to result in
Fig. 1. PTPR mutations correlate with STAT3 tyro-
sine phosphorylation in HNSCC tumors and enhance
survival and STAT3 phosphorylation in HNSCC cells.
(A) Significant increase in p-STAT3(Y705) expression
(intensity plot in log2 scale; protein array data from
The Cancer Proteome Atlas) in HNSCC patient
tumors harboring PTPRD/J/K/M/O/S/T mutation (n =
37) vs. tumors without PTPRT mutation (n = 171)
(P = 0.0202*). (B) Serum-dependent PCI-52-SD1 cells
stably expressing EGFP-vector control, wild-type
PTPRT, or PTPRT(A1022E) or (R1040L) mutants were
assessed by MTT assay for growth in the absence of
serum. Cumulative growth relative to vector control
(n ≥ 9) is shown. (C) Stable expression of wild-type
PTPRT reduced basal p-STAT3(Tyr705) expression in
PCI-52-SD1 cells. Graph showing cumulative results
of p-STAT(Y705) levels in these cells from five in-
dependent experiments. (D) CAL-33 cells were tran-
siently transfected with a representative PTPase-
domain mutation (A1022E) and an FN3-domain
mutation (P497T). Expression levels of p-STAT3
(Tyr705) were detected by Western blotting. The
PTPase domain mutation, but not the FN3-domain
mutation, increased p-STAT3(Tyr705) expression.
Similar results were observed in three independent
experiments.











both charge and amino acid size changes) (Table S1), PTPRT
(A1022E) and PTPRT(R1040L), conferred increased survival
(3.2- and 6.2-fold, respectively) compared with expression of
empty vector control, confirming a driver phenotype for these
PTPRT mutants in HNSCC cells (Fig. 1B).
To investigate the mechanism responsible for the driver pheno-
type of the PTPRT mutants, we tested the hypothesis that PTPRT
mutations identified in HNSCC may impair the phosphatase ac-
tivity of the enzyme, resulting in increased phosphorylation of
PTPRT substrates, including the oncogenic transcription factor
STAT3. Stable expression of wild-type PTPRT in PCI-52-SD1 cells
resulted in reduction of basal p-STAT3 levels by∼48% (P= 0.0014)
(Fig. 1C), demonstrating that wild-type PTPRT can modulate
STAT3 activation in HNSCC cells. On the other hand, expression
of a PTPRT protein harboring a mutation (A1022E) in the catalytic
domain promoted up-regulation of the p-STAT3 protein in an
HNSCC cell line with low basal levels of p-STAT3 (CAL-33) (Fig.
1D). Similar effects were observed in HEK293 cells upon transient
expression of a PTPRT mutant (Fig. S3). Interestingly, expression
of a PTPRT protein with a mutation (P497T) in the extracellular
fibronectin type III-like domain did not alter the phosphorylation
status of STAT3 (Fig. 1D), suggesting that mutations outside the
catalytic domains may have other mechanisms of action. In addi-
tion, expression of wild-type PTPRT in EGFR-knockout mouse
embryonic fibroblasts resulted in decreased expression of p-STAT3
(Y705), suggesting that PTPRT catalytic activity is independent of
EGFR expression/activity (Fig. S4).
Computational Modeling of PTPRT Mutations in the Substrate Binding
Sites Reveals Plausible Functional Alterations of Phosphatase Activity.
Given that a high percentage of PTPRT mutations are located
within the enzymatic (PTPase) domain, we sought to determine
the potential impact of these mutations on interactions between
the catalytic domains and phospho-tyrosine substrate using a
molecular modeling approach. Although the structure of a
PTPRT–p-Tyr protein complex is not available, the X-ray crys-
tallographic structure of the PTPRT phosphatase domain alone
has been reported (PDB ID code 2OOQ) (8). Therefore, we
determined by homology modeling (9), the approximate sub-
strate-interacting surface of the PTPRT PTPase domains 1 and 2
(Fig. 2 A–D) based on the highly similar (to PTPRT) crystal
structure of human tyrosine phosphatase PTPN5 in complex with
p-Tyr (detailed in Materials and Methods). Using this model, we
localized several cancer-related PTPRT mutation sites to the
substrate-interaction surface of the PTPRT PTPase domains 1
and 2 in close proximity to incorporated p-Tyr (D905, R928,
H1053, G1089, and V1124 in domain 1; Q1180, R1201, R1207,
P1213, Q1286, T1346, N1380, G1382, and R1384 in domain 2).
Mutation sites previously shown to decrease the PTPRT phos-
phatase activity were also found in proximity to p-Tyr regions
(C1084, D1052, Y893, Q965, R1188, and T1346) (10, 11). These
results suggest that PTPRT PTPase domain mutations, which are
found in human cancers, likely interfere with enzymatic activity
and/or substrate interactions. Of note, in addition to the repor-
ted missense mutations of the PTPRT PTPase domains, many
nonsense mutations (mutation to a stop codon) and frameshift
mutations are highly likely to alter PTPRT structure and stability,
as well as impacting substrate interactions (L362fs, R617fs, Q434*,
and Q615* found in HNSCC, and E1227*, R1207*, E1155*,
R1358*, and G1386* in other cancers; COSMIC database).
PTPR Genes Are Mutated in Nearly One-Third of HNSCC Tumors, and
PTPRT Is the Most Frequently Mutated PTPR. PTPRT belongs to the
receptor protein tyrosine phosphatase family, which comprises
21 members, and no genomic study to date has examined the
mutational profile of the entire family in a large number of hu-
man tumor specimens. To understand the potential genetic
contributions of the PTPR family (in addition to PTPRT) to ty-
rosine signaling/regulation in head and neck squamous cell car-
cinoma (HNSCC), we comprehensively analyzed PTPR family
mutations in large cohorts of primary HNSCC tumors. Whole-
exome sequencing data of 374 primary HNSCCs were included
[from 300 TCGA HNSCC tumors and 74 HNSCCs previously
published (12)]. Strikingly, 30.7% (115/374) of HNSCC tumors
harbored nonsynonymous somatic mutations of at least one PTPR
family member, compared with only 15.2% (57/374) of tumors with
mutations of cytoplasmic PTP genes, the second major family of
PTPs (Fig. 3A). Further, 7.8% (29/374) of HNSCC tumors con-
tained multiple mutations of PTPR family members (from two to
six PTPR mutations/tumor) (Fig. 3B) (Table S2 contains all PTPR
mutations found in HNSCC). Further investigation demonstrated
that this high rate of somatic mutation of the PTPR family (vs.
cytoplasmic PTPs) found in HNSCC is also detected in all 14 types
of human solid tumors sequenced to date by The Cancer Genome
Atlas (TCGA) (4,039 total solid tumors sequenced), but not in
a hematopoietic malignancy (6/196 AML cases; 3.1%) (Fig. 3C and
Table S3), implicating a likely pathologic involvement of PTPR
mutations in HNSCC, as well as other solid human tumors.
Human papilloma virus (HPV) infection is a known etiologic
factor in a subset of HNSCC and is capable of disrupting genome
stability. Thus, we examined whether HPV was associated with the
high rate of PTPRmutations inHNSCC. Statistical analysis showed
no correlation between PTPRmutation and HPV status (P = 0.31;
PTPR mutations in 11/48 HPV-positive tumors vs. 93/299 HPV-
negative tumors), indicating that HPV is not a contributing factor
to PTPRmutations in HNSCC. Further analysis showed that PTPR
mutations were not associated with mutations of TP53 (P = 0.81),
NOTCH1 (P = 0.24), PIK3CA (P = 0.47), or HRAS (P = 0.77) in
HNSCC, indicating that PTPR mutations are independent of
these known commonmutational events in HNSCC tumors (12).
The availability of comprehensive whole-exome sequencing
data (from TCGA) on all PTPR genes allowed us to identify the
most commonly mutated PTPRs in all sequenced human cancers,
including HNSCC. Among the 374 sequenced HNSCC tumors,
PTPRT is the most frequently mutated PTPR (5.6% cases; 22
mutations total, with one tumor harboring 2 PTPRT mutations),
followed by PTPRC, PTPRD, and PTPRM (Table S2). Although
PTPR mutation rates vary among different cancer types, cumu-
lative results reveal that PTPRT is the single most commonly
mutated PTPR in human cancers (6.2%, 285 mutations in 4,609
solid and hematopoietic cancers sequenced) (Table S3), with the
highest mutation frequency of PTPRT in cutaneous melanoma
(a total of 99 mutations in 253 tumors sequenced; 39.1%).
The sites of the most frequently mutated PTPR members
(PTPRT/C/D/M) in HNSCC are shown in Fig. 3D (all other
HNSCC-associated PTPR mutations are shown in Fig. S5). Cu-
mulative mutation data for PTPRT in 16 types of sequenced
tumors indicate that 37.9% (108/285) of PTPRT mutations are
found in the catalytic phosphatase (PTPase) domain whereas
33.0% (94/285) occur in the extracellular fibronectin type III-like
(FN3) domain. In HNSCC, 45.5% (10/22) of PTPRTmutations are
located in the PTPase domain (Fig. 3D), indicating the pathologic
relevance of these genetic alterations of the phosphatase activity,
which lead to pSTAT3 up-regulation in HNSCC tumors.
Discussion
These cumulative results indicate that selected tumor-associated
PTPRT mutations can alter STAT3 phosphorylation/activation.
Our findings suggest a previously undescribed, and potentially
common, mechanism for dysregulated cell survival and growth in-
volving PTPR mutation and STAT3 hyperactivation. Therefore,
tumors that harbor PTPR (including PTPRT) mutations may be
amenable to treatment with STAT3 pathway inhibitors. The fre-
quency of PTPR mutations is unexpectedly high across all solid
tumor types analyzed to date. The dispersed distribution and lack
of hotspot mutations in PTPR genes suggest that these mutations
likely represent loss-of-function events affecting tumor suppressive
proteins rather than gain-of-function of oncogenic proteins in
cancer. Although this mutation pattern is consistent with that
reported for select PTPRs in colorectal cancers (10), this study
represents a comprehensive analysis of somatic mutations of the
entire PTPR family across all human cancers sequenced to date.
Constitutive STAT3 activation is frequently found in nearly
all human cancers, and expression levels of p-STAT3(Y705)
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are often associated with poor prognosis (13–15). Mechanisms
driving STAT3 activation in cancer are incompletely understood.
Direct sequencing of thousands of patient tumors by TCGA
has not identified common or consistent STAT3 mutational
events in solid tumors. Furthermore, solid tumors, including
HNSCC, exhibit a lack of activating mutations in kinases upstream
Fig. 2. Computational modeling of PTPRT PTPase domain in complex with a phospho-tyrosine substrate. (A) PTPRT PTPase domain 1 in complex with
phospho-tyrosine (p-Tyr, green) of substrate (e.g., p-STAT3). The surface involved in the interaction with partner (p-Tyr-containing) protein is divided into
three regions, residues within 0–5 Å from p-Tyr (red), 5–12 Å (purple), and 12–25 Å (cyan). Positions found to be mutated in human cancers are indicated by
“c”; trapping mutations by “Δ” (6); other experimentally verified loss-of-function mutations by “e” (10, 11). (B) Detailed view of the catalytic site. The largest
part of the catalytic site in domain 1 is formed by the loop region (from the catalytic C1084-G1092). Positively charged R1090 and K996 are involved in the
electrostatic interaction with the negatively charged phosphate group of p-Tyr. The aromatic part of p-Tyr is further stabilized by hydrophobic interactions
with Y918 and I921. (C) Structure of the PTPRT PTPase domain 2 in complex with p-Tyr (green) of the binding partner (e.g., p-STAT3). Annotations are as in B.
Potential trapping mutations based on homology with domain 1 are indicated by “Δ”. (D) Detailed view of the catalytic site of the PTPRT PTPase domain 2.











of STAT3 (4). Thus, activating mutations of STAT3, or of direct
upstream positive regulators, are unlikely to be the key genetic
factors driving STAT3 hyperactivation in human cancers. PTPRT
has been reported to be a negative regulator of STAT3 (6). Our
integrative genomic-proteomic findings establish that PTPRT
mutations are important genetic events that drive in situ up-
regulation of p-STAT3(Y705) within patient tumors. This
reveals the driver role of genetic mutations in a negative regu-
lator(s) of STAT3, an important oncogenic signaling protein in
human cancer. PTPRT has been previously shown to be a tumor
suppressor (in colon cancer cell line models), consistent with our
present findings (16). Our results suggest that loss-of-function
mutations in tumor suppressor tyrosine phosphatases may not
only serve as permissive factors for oncogenesis as previously
demonstrated, but can also act as direct drivers for cancer cell
growth via dysregulation of substrate tyrosine phosphorylation.
Studies of PTPRT, in particular, showed that PTPRT has a
discretely defined set of substrates, including STAT3 and paxillin. In
our current study, the correlation between paxillin phosphorylation
and PTPRT mutations was not examined, as anti–phospho-paxillin
antibody has not been validated for our protein array platform.
However, it is possible that paxillin signaling may also be affected
by PTPRT mutations in the human tumors.
Computational modeling allows us to predict the potential
effects of PTPase domain mutations (located intracellularly)
in PTPRT, which may be applicable to other RPTP proteins.
However, there are no existing computational methodologies to
reliably predict the effects of the extracellular domain mutations
(such as the FN3 domain mutations) found in these proteins.
The broad existence of these extracellular domain mutations in
the RPTP family will require systematic functional validation of
each mutation in relevant cell models, as we have previously shown
that some of these mutations could alter cell–cell adhesion, and
thereby promote tumor cell migration (17).
The present study demonstrates that wild-type PTPRT pro-
motes down-regulation of p-STAT3(Y705) in HNSCC and that
somatic PTPRT mutations may represent “driving” events in
cancer. We identify that somatic PTPR mutations, including
PTPRT mutations, are associated with elevated p-STAT3(Y705)
in human HNSCC. Other RPTP family members, especially
PTPRD, may play similar roles in HNSCC and other solid
tumors, where somatic mutation may lead to loss-of-function
and subsequent activation of oncogenic pathways. Indeed, several
commonly mutated PTPRs have been implicated as tumor
suppressors, including PTPRD (18), PTPRF (10), PTPRG (10, 19),
PTPRJ (20), and PTPRS (21).
Fig. 3. Whole-exome sequencing of human cancers demonstrates high rates of PTPR somatic mutations. (A) Frequencies of PTPR (the receptor subtype) and
cytoplasmic PTP somatic mutations in 374 HNSCC tumors. (B) A subset (29/374, 7.8%) of HNSCC tumors harbor mutations of multiple PTPR genes. (C) The PTPR
gene family is mutated at a higher rate than the cytoplasmic PTP gene family across 15 cancers [cBio portal (24)]. AD, adenocarcinoma; AML, acute myeloid
leukemia; GBM, glioblastoma multiforme; SCC, squamous cell carcinoma. (D) Mutation and domain-mapping of the four most frequently mutated RPTPs in
HNSCC. Domains defined as in the Swiss-Prot entries, Protein Knowledgebase, and UniProtKB.
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In conclusion, PTPR mutational events are relatively common
in primary HNSCC, as well as in many other solid tumors as
revealed by large-scale whole-exome sequencing studies. We
demonstrate that tumor-specific mutational events in the PTPRT
gene can serve as direct drivers for tumor growth by inducing
hyperactivation of STAT3, a potent oncogenic transcription factor
and PTPRT substrate. STAT3 pathway inhibitors are under active
investigation in human cancers and include transcription factor
decoys, disruptors of recruitment of STAT3 to the IL6/IL6Ralpha/
gp130 complex, and upstream kinase inhibitors, primarily Janus
kinase inhibitors (22, 23). It is biologically plausible that selected
PTPR mutations may identify tumors that may be particularly
responsive to treatment with STAT3 pathway inhibitors.
Materials and Methods
Mutation Databases. HNSCC mutation analyses were based on the published
whole-exome sequencing data on 74 HNSCC tumors (12) and TCGA. PTPR and
cytoplasmic PTP family mutation rates (% mutated tumors) were calculated
by the actual percent of tumors harboring nonsynonymous mutations of PTPR
or cytoplasmic PTP family members. For multicancer analysis, mutation data
(from whole-exome sequencing) were obtained from the cBio portal (24).
Proteomic Analysis. Quantitative proteomic analysis (reverse phase protein
array) of p-STAT3(Y705) was performed on 212 HNSCC tumors (a subset of the
374 tumors in this study). Data were obtained from The Cancer Proteome
Atlas (TCPA) database (http://app1.bioinformatics.mdanderson.org/tcpa/_design/
basic/index.html). Phospho-STAT3(Y705) expression levels of the PTPR-WT
versus PTPR-mutated tumors were compared using a two-tailed t test in
GraphPad Prism 5 software (GraphPad).
Cell Cultures. All HNSCC cell lines were genotypically verified and grown in
a humidified cell incubator at 37 °C and 5% (vol/vol) CO2. CAL-33, Cal27, FaDu,
and PCI-52 cells were maintained in complete DMEM containing 10% FBS and
1× penicillin/streptomycin solution (Invitrogen) whereas PE/CA-PJ34.12 and PE/
CA-PJ49 cells were maintained in IDMEM containing 10% (vol/vol) FBS and 2
mM L-glutamine. Cal27 and FaDu cell lines were obtained from ATCC whereas
PE/CA-PJ34.12 and PE/CA-PJ49 cells were obtained from Sigma-Aldrich. CAL-33
cells were obtained from Gerard Milano (Centre Antoine Lacassagne, Nice,
France), and the PCI-52-SD1 cell line was obtained by clonal selection of the
parental PCI-52 cell line (University of Pittsburgh Cancer Institute) by rounds
of graded serum selection. In brief, PCI-52 parental cell lines were plated as
single cells, which grew as single clones. These single clones were subjected
to serum deprivation (0% FBS) for 1–2 wk, followed by assessment of cell
growth by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide
(MTT) assay. The PCI-52-SD1 subline was the most serum-sensitive subline,
which died (>99.8%) upon complete serum deprivation.
Plasmid Constructs and Site-Directed Mutagenesis. pCI-Neo-PTPRT was obtained
from Addgene (plasmid 16630). pMXs-puro-EGFP vector was obtained from Cell
Biolabs. PTPRTWT gene was subcloned into the retroviral vector, and the pMXs-
puro-PTPRT WT was used as a template for site-directed mutagenesis using the
QuikChange Site-Directed Mutagenesis Kit according to the manufacturer’s
instructions (Stratagene). All mutation sites as well as the full-length cDNA were
sequence confirmed.
Retroviral Infection of HNSCC Cells. Retroviruses were generated using the
Platinum Retrovirus Expression Systems (Cell Biolabs) according to the
manufacturer’s instructions. Briefly, Plat-A cells were transfected with 3 μg
of retroviral vector carrying the gene of interest (pMXs-puro-EGFP as con-
trol, pMXs-puro-PTPRT WT, pMXs-puro-PTPRT mutants). Three days after
transfection, fresh retroviruses (in the supernatant of the Plat-A cells) were
collected by centrifugation at 1,200 × g for 5 min at 4 °C. Cell debris was
removed by filtering through a 0.45-μm syringe filter. Fresh retroviruses
were used for infection of HNSCC cells. HNSCC cells were plated at 20%
confluency in a T75 flask 1 d before infection. Infection of HNSCC cells was
performed by adding 4.5 mL of retrovirus to the cells containing 7.5 mL of
complete culture media. Then, 38 μL of polybrene (4 μg/μL; Sigma-Aldrich)
was added to the cells with gentle mixing. Cells were then incubated at 37 °C
and 5% CO2 for an additional 48–72 h, and the infection mediumwas replaced
with fresh complete medium. Expression of the gene of interest and alteration
of the signaling pathway were assessed within 7–10 d of infection.
Immunoblotting. Primary antibodies for p-STAT3(Tyr705) and STAT3 were
purchased from Cell Signaling Technology. PTPRT antibody was produced by
Z.W. Anti-tubulin antibody was from Abcam, and secondary antibodies were
from BioRad. Blots were quantitated by densitometry using ImageJ software.
Molecular Modeling. The crystal structure of human PTPRT catalytic domain 1
(PDB ID code 2OOQ) (8) and the crystal structure of catalytic domains 1 and 2 of
human protein phosphatase gamma (PDB ID code 2NLK) (8) were used as
templates for homology modeling of human PTPRT (amino acids 862–1441,
covering the PTPase domains 1 and 2) using the program Modeler version 9v8
(9). A substrate, p-Tyr, was modeled into the catalytic sites of both domains 1
and 2 of PTPRT upon superposition with the highly similar crystal structure of
the human tyrosine phosphatase PTPN5 (also known as STEP) (C472S catalyt-
ically inactive mutant) in complex with p-Tyr (PDB ID code 2CJZ) (the root-
mean-square deviation between 2OOQ and 2CJZ is 1.85 Å). Surface residues of
the PTPRT PTPase domain 1 and 2 were divided into three groups according to
their distance from the bound p-Tyr (within 0–5 Å, 5–12 Å, and 12–25 Å).
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